Acelyrin, Inc. (SLRN) Stock

About Acelyrin, Inc.

Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A. This compound is currently undergoing Phase 3 clinical evaluations for its use in treating Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis. Additionally, izokibep is being assessed in Phase 2 clinical trials for Axial Spondyloarthritis. Beyond izokibep, Acelyrin is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the insulin-like growth factor 1 receptor. Lonigutamab is in Phase 1 clinical studies for individuals with thyroid eye disease. Furthermore, the company has SLRN-517, a fully human IgG1 monoclonal antibody aimed at c-KIT, which is in the preclinical stage of development for the treatment of chronic urticaria. Founded in 2020, Acelyrin's corporate headquarters are located in Agoura Hills, California.

Acelyrin, Inc. is headquartered in US.

Acelyrin, Inc. (SLRN) stock trades at $2.27 with a market capitalization of $229.17M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.91, reflecting a net loss over the last twelve months, price-to-book of 0.49, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.85 and $7.25, and currently trades 68.7% below its 52-week high.

On profitability, Acelyrin, Inc. generates a return on equity (ROE) of -44.54% (negative, reflecting a net loss), return on capital employed of -68.08%.

Official website: www.acelyrin.com